1. 2022-RA-576-ESGO Expression VIII – first study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 321 patients. (20th October 2022) Authors: Beckmann, Laura Naomi; Alavi, Sara; Keller, Maren; Liebrich, Clemens; Kubiak, Karol; Wimberger, Pauline; Czolk, Vera; Ligl-Löhner, Anette; Enzinger, Hans-Martin; Burdack, Aline; Fischer, Dorothea; Terhaag, Jürgen; Müller, Cornelia; Hanf, Volker; Condic, Mateja; Kunz, Georg; Lantzsch, Tilmann; Sch... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018) Authors: Colleoni, Marco; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seam... Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗